LONDON, January 8, 2018 /PRNewswire/ --
Medical Devices continue to transform the future of the healthcare industry,but increasing industry competition and consumer adoption had driven regulatory agencies to increase the quality and compliance metrics associated with medical device development through ever increasing regulatory scrutiny. In this changing landscape,
Recent security scandals and the proliferation of 'additions' to conventional medical devices continue to drive increases in regulatory authority scrutiny and more stringent requirements for medical device development. The MEDDEV 2.7.1 Rev 4 updates have paved the way for the new MDR, but implementation cannot happen overnight, and the timeline for compliance needs to start now.
To help the industry comply with regulations, the Medical Device Pathways forum will feature advice and guidance from the industry's leading experts, providing your company with the opportunity to get to grips with your key regulatory and compliance challenges, and industry specific networking opportunities, making this event Europe's leading forum for ensuring your pathway to approval is ahead of your competition.
In an exclusive interview with Tobias Schreiegg, Director of Quality and Regulatory Affairs Management at Siemens Healthcare and Dorota Johansson, Clinical and Research Director at Bactiguard, Pharma IQ learn more on the impact the MDR will have on both organisations and within the broader medical device industry, how different organisations are preparing for compliance and best practices for communicating regulatory changes throughout an organization. View the interview here
SOURCE Pharma IQ
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All